
Part I. Financial Information Item 1. Financial Statements The unaudited condensed consolidated financial statements for the quarter ended June 30, 2024 are presented Condensed Consolidated Balance Sheets%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $133.80 million from $170.95 million, driven by a reduction in short-term investments Key Balance Sheet Metrics | Metric | June 30, 2024 (Unaudited) | December 31, 2023 | | :--------------------------------------- | :-------------------------- | :------------------ | | Cash and cash equivalents | $34,392,404 | $14,310,862 | | Short-term investments | $76,029,116 | $130,982,913 | | Total current assets | $117,561,045 | $153,113,100 | | Total assets | $133,797,203 | $170,951,423 | | Total current liabilities | $26,399,768 | $42,570,228 | | Total liabilities | $37,057,996 | $53,602,294 | | Total stockholders' equity | $96,739,207 | $117,349,129 | Condensed Consolidated Statements of Operations%20Condensed%20Consolidated%20Statements%20of%20Operations) Net loss improved to $32.24 million for Q2 2024 from $35.53 million in the prior year period, despite a significant decrease in revenue Three Months Ended June 30 | Metric | 2024 | 2023 | | :-------------------------------------------------- | :------------------------------- | :------------------------------- | | Revenue from collaborative arrangements and other contracts | $100,762 | $225,971 | | Research and development expenses | $23,090,989 | $23,743,970 | | General and administrative expenses | $10,206,686 | $13,523,098 | | Total operating expenses | $33,297,675 | $37,267,068 | | Loss from operations | $(33,196,913) | $(37,041,097) | | Net loss | $(32,237,098) | $(35,534,533) | | Net loss per share (Basic and diluted) | $(1.19) | $(1.61) | Six Months Ended June 30 | Metric | 2024 | 2023 | | :-------------------------------------------------- | :----------------------------- | :----------------------------- | | Revenue from collaborative arrangements and other contracts | $100,762 | $340,914 | | Research and development expenses | $44,001,307 | $53,920,481 | | General and administrative expenses | $20,781,337 | $27,413,708 | | Total operating expenses | $64,782,644 | $81,334,189 | | Loss from operations | $(64,681,882) | $(80,993,275) | | Net loss | $(62,706,969) | $(76,183,850) | | Net loss per share (Basic and diluted) | $(2.48) | $(3.50) | Condensed Consolidated Statements of Comprehensive Loss%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Comprehensive loss was $32.25 million for Q2 2024 and $62.73 million for the six-month period Three Months Ended June 30 | Metric | 2024 | 2023 | | :------------------------------------------- | :------------------------------- | :------------------------------- | | Net loss | $(32,237,098) | $(35,534,533) | | Other comprehensive loss: | | | | Foreign currency translation | $0 | $(376) | | Unrealized (loss) gain on short-term investments, net of tax | $(13,322) | $(108,089) | | Comprehensive loss | $(32,250,420) | $(35,642,998) | Six Months Ended June 30 | Metric | 2024 | 2023 | | :------------------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(62,706,969) | $(76,183,850) | | Other comprehensive loss: | | | | Foreign currency translation | $32,403 | $(2,294) | | Unrealized (loss) gain on short-term investments, net of tax | $(59,338) | $9,773 | | Comprehensive loss | $(62,733,904) | $(76,176,371) | Condensed Consolidated Statements of Stockholders' Equity%20Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Total stockholders' equity decreased to $96.74 million from $117.35 million due to net losses, partially offset by stock issuances Stockholders' Equity Overview | Metric | December 31, 2023 | June 30, 2024 | | :----------------------------------- | :---------------- | :---------------- | | Common stock | $22,792 | $25,962 | | Additional paid-in capital | $1,740,954,074 | $1,783,074,886 | | Accumulated deficit | $(1,622,965,136) | $(1,685,672,105) | | Total stockholders' equity | $117,349,129 | $96,739,207 | - Issuance of common stock for cash, net of financing costs, contributed $5.2 million and $17.06 million during the three months ended March 31, 2024, and three months ended June 30, 2024, respectively11 - Issuance of pre-funded warrants for cash, net of financing costs, contributed $16.15 million during the three months ended June 30, 202411 Condensed Consolidated Statements of Cash Flows%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net increase in cash was $20.08 million for the six months ended June 30, 2024, driven by financing activities Six-Month Cash Flow Summary | Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(56,969,306) | $(68,979,134) | | Net cash provided by investing activities | $55,348,949 | $72,906,429 | | Net cash provided by financing activities | $21,669,496 | $2,458,183 | | Increase in cash and cash equivalents | $20,081,542 | $6,383,184 | | Cash and cash equivalents, end of period | $34,392,404 | $52,712,543 | - Financing activities in 2024 included $16.15 million from pre-funded warrants and $22.28 million from common stock issuance, offset by $16.42 million repayment of convertible senior notes16 Notes to Condensed Consolidated Financial Statements%20Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's financial position, operations, accounting policies, and liquidity challenges 1. Organization and Operations Inovio is a clinical-stage biotechnology company developing DNA medicines with its lead candidate, INO-3107 - Inovio is a clinical-stage biotechnology company developing DNA medicines for HPV, cancer, and infectious diseases18 - The company's platform uses proprietary technology to design DNA plasmids and CELLECTRA delivery devices18 - INO-3107 is the lead candidate for recurrent respiratory papillomatosis (RRP), showing 81.3% of patients experienced a reduction in surgical interventions in a Phase 1/2 trial18 2. Basis of Presentation, Liquidity and Risks and Uncertainties The company incurred a Q2 net loss of $32.2 million and raised $33.2 million to fund operations for at least 12 months - Net loss for Q2 2024 was $32.2 million, and $62.7 million for the six months ended June 30, 202421 - Accumulated deficit reached $1.7 billion as of June 30, 202421 - A registered direct offering in April 2024 generated $33.2 million in net proceeds, expected to support operations for at least 12 months21 - A 1-for-12 reverse stock split was effected in January 202421 3. Critical Accounting Policies Critical accounting policies include revenue recognition for collaboration agreements and clinical trial accruals - Collaboration agreements are assessed under ASC Topic 808 or Topic 606 for revenue recognition23 - Research and development expenses, especially clinical trial accruals, are based on estimates of total costs incurred, subject to revisions as trials progress24 4. Short-term Investments and Fair Value Measurements Short-term investments totaled $76.03 million, down from $130.98 million, with an unrealized loss of $3.5 million Short-term Investment Portfolio | Investment Type | June 30, 2024 Fair Market Value | December 31, 2023 Fair Market Value | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Mutual funds | $42,498,607 | $51,866,401 | | U.S. treasury securities | $29,674,100 | $75,189,720 | | Certificates of deposit | $2,990,036 | $2,990,326 | | U.S. agency mortgage-backed securities | $866,373 | $936,466 | | Total short-term investments | $76,029,116 | $130,982,913 | - Aggregate total unrealized loss on available-for-sale securities was $3.5 million as of June 30, 2024, primarily due to changes in interest rates2728 5. Certain Balance Sheet Items Accounts payable and accrued expenses decreased to $16.63 million, while prepaid assets remained stable Selected Balance Sheet Items | Metric | June 30, 2024 | December 31, 2023 | | :----------------------------------- | :------------ | :---------------- | | Prepaid clinical expenses | $2,341,285 | $3,410,442 | | Other prepaid expenses | $3,024,575 | $1,983,223 | | Total prepaid and other current assets | $5,365,860 | $5,393,665 | | Trade accounts payable | $4,487,282 | $3,577,826 | | Accrued compensation | $8,642,497 | $9,837,104 | | Other accrued expenses | $3,504,982 | $6,432,814 | | Total accounts payable and accrued expenses | $16,634,761 | $19,847,744 | - Accrued clinical trial expenses increased from $2.37 million to $5.50 million6 6. Convertible Debt The remaining $16.9 million of convertible senior notes matured and were paid in full on March 1, 2024 - Convertible senior notes matured on March 1, 2024, with the remaining $16.9 million obligation paid in full35 Interest Expense on Convertible Notes | Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------- | :----------------------------- | :----------------------------- | | Interest expense | $178,000 | $627,000 | 7. Stockholders' Equity An April 2024 offering of common stock and pre-funded warrants generated $33.2 million in net proceeds Stock Outstanding | Stock Type | Authorized | Issued (June 30, 2024) | Outstanding (June 30, 2024) | Outstanding (December 31, 2023) | | :----------------------------------- | :----------- | :--------------------- | :-------------------------- | :------------------------------ | | Common Stock, par value $0.001 per share | 600,000,000 | 25,963,544 | 25,963,544 | 22,793,075 | | Series C Preferred Stock, par value $0.001 per share | 1,091 | 1,091 | 9 | 9 | - In April 2024, the company closed an offering of 2,536,258 common shares and pre-funded warrants for 2,135,477 shares, yielding $33.2 million net proceeds37 - The 2021 ATM Equity Offering Sales Agreement was terminated in August 2024, having sold 4,289,403 shares for $93.6 million net proceeds146 8. Net Loss Per Share Net loss per share improved to $(1.19) for Q2 2024 and $(2.48) for the six-month period Three Months Ended June 30 | Metric | 2024 | 2023 | | :-------------------------------------------------------------------------------- | :------------------------------- | :------------------------------- | | Net loss | $(32,237,098) | $(35,534,533) | | Weighted-average common shares outstanding used to compute basic and diluted net loss per share | 27,197,802 | 22,029,486 | | Net loss per share (Basic and diluted) | $(1.19) | $(1.61) | Six Months Ended June 30 | Metric | 2024 | 2023 | | :-------------------------------------------------------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(62,706,969) | $(76,183,850) | | Weighted-average common shares outstanding used to compute basic and diluted net loss per share | 25,244,657 | 21,784,343 | | Net loss per share (Basic and diluted) | $(2.48) | $(3.50) | - Potentially dilutive securities, including stock options, RSUs, and convertible preferred stock, were anti-dilutive for both periods due to net losses4145 9. Stock-Based Compensation Stock-based compensation expense decreased to $1.5 million for Q2 2024 and $3.9 million for the six-month period Stock-Based Compensation Expense | Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | | :------------------------------------------------ | :------------------------------- | :----------------------------- | | Total employee and director stock-based compensation expense | $1.5 million | $3.9 million | | Included in research and development expenses | $581,000 | $1.6 million | | Included in general and administrative expenses | $890,000 | $2.3 million | - Unrecognized compensation expense for unvested stock options was $3.7 million, expected over 1.6 years48 - 82,000 performance- and market-based RSUs were granted in May 2024, with Milestone-based RSUs valued at $629,000 and Market-based RSUs at $263,0004950 10. Related Party Transactions The company maintains related party transactions with Plumbline Life Sciences and The Wistar Institute - Inovio owns 17.8% of Plumbline Life Sciences, Inc. (PLS)52 - Collaborative research agreements with The Wistar Institute involve DNA-based immunotherapy and vaccine development, with contra-research and development expense of $9,000 for Q2 2024 and $149,000 for the six months, down from $179,000 and $390,000 in 202352 11. Commitments and Contingencies Operating lease liabilities total $12.98 million, and the company is involved in ongoing legal proceedings Future Lease Payments | Year | Lease Payments | | :-------------------------- | :------------- | | Remainder of 2024 | $1,696,000 | | 2025 | $3,467,000 | | 2026 | $3,555,000 | | 2027 | $2,955,000 | | 2028 | $2,310,000 | | Thereafter | $2,132,000 | | Total remaining lease payments | $16,115,000 | | Less: present value adjustment | $(3,135,000) | | Total operating lease liabilities | $12,980,000 | - The company is actively prosecuting claims against VGXI for breach of supply agreement and defending against counterclaims5860 - The company is prosecuting counterclaims against GeneOne for breach of the CELLECTRA Device License Agreement and defending against GeneOne's claims; a motion for summary judgment was denied in June 202461 12. Collaborative Agreements The company maintains collaborative agreements with Advaccine, ApolloBio, CEPI, and the Gates Foundation - Advaccine continues to develop INO-4800 in Greater China, with no funding received by Inovio in 2024, compared to $1.2 million and $2.4 million in Q2 and YTD 2023, respectively64 - ApolloBio Corporation is developing VGX-3100, with Inovio receiving $101,000 in funding in 202467 - CEPI funding for Lassa fever, MERS, and INO-4800 vaccine candidates ceased in 2024, compared to $438,000 and $2.09 million in Q2 and YTD 2023, respectively67 - Gates Foundation grant for DMAb development provided $39,000 in YTD 2024, down from $70,000 in YTD 202368 13. Income Taxes No income tax provision or benefit was recorded due to a history of net operating losses - No income tax provision or benefit was recorded for the six months ended June 30, 2024 and 202369 - This is due to a history of net operating losses and a full valuation allowance against net deferred tax assets69 14. Geneos Therapeutics, Inc. The investment in Geneos Therapeutics is accounted for using the equity method, with no further investments planned - Inovio deconsolidated Geneos Therapeutics in 2020 and now uses the equity method for its investment70 - As of 2023, Inovio held approximately 23% of Geneos's outstanding equity on an as-converted basis71 - Inovio has not made further investments in Geneos since March 2022 and will not record its share of further net losses70 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management discusses financial performance, liquidity, and future funding needs to advance its DNA medicine pipeline Overview A manufacturing issue with the CELLECTRA 5PSP device will delay the BLA submission for lead candidate INO-3107 to mid-2025 - Inovio is a clinical-stage biotechnology company focused on DNA medicines for HPV, cancer, and infectious diseases, delivered by proprietary CELLECTRA devices7475 - INO-3107 for RRP showed 81.3% of patients experienced reduced surgical interventions in a Phase 1/2 trial, with FDA feedback supporting BLA submission under accelerated approval75 - A manufacturing issue with the CELLECTRA 5PSP device will likely delay INO-3107 BLA submission until mid-202575 - The company had an accumulated deficit of $1.7 billion as of June 30, 2024, and expects continued operating losses76 Critical Accounting Policies and Estimates No significant changes have been made to the company's critical accounting estimates since December 31, 2023 - No significant changes to critical accounting estimates since December 31, 202377 - Critical accounting estimates include collaboration agreements, revenue recognition, and clinical trial accruals77 Results of Operations Operating expenses decreased due to discontinued programs and lower compensation, partially offset by increased INO-3107 costs Three-Month Results of Operations | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Change (%) | | :----------------------------------- | :------------------------------- | :------------------------------- | :--------- | | Revenue | $101,000 | $226,000 | (55.4%) | | R&D Expenses | $23,091,000 | $23,743,000 | (2.7%) | | G&A Expenses | $10,207,000 | $13,523,000 | (24.5%) | | Interest Income | $1,307,000 | $2,168,000 | (39.7%) | | Interest Expense | $0 | $313,000 | (100.0%) | | Net Unrealized (Loss) Gain on Available-for-Sale Equity Securities | $(21,000) | $923,000 | (102.3%) | Six-Month Results of Operations | Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | Change (%) | | :----------------------------------- | :----------------------------- | :----------------------------- | :--------- | | Revenue | $101,000 | $341,000 | (70.4%) | | R&D Expenses | $44,001,000 | $53,921,000 | (18.4%) | | G&A Expenses | $20,781,000 | $27,414,000 | (24.2%) | | Interest Income | $2,808,000 | $4,375,000 | (35.8%) | | Interest Expense | $178,000 | $627,000 | (71.6%) | | Net Unrealized (Loss) Gain on Available-for-Sale Equity Securities | $480,000 | $4,141,000 | (88.4%) | - Decrease in R&D expenses was primarily due to lower drug manufacturing and clinical study expenses for discontinued programs (INO-4800, VGX-3100), lower employee compensation, and a non-recurring impairment charge in 2023, partially offset by higher INO-3107 manufacturing and device development costs82 - General and administrative expenses decreased due to lower employee compensation and reduced legal expenses from settled litigation82 Liquidity and Capital Resources Cash and investments totaled $110.4 million, with a cash runway expected to extend into Q3 2025 Liquidity Position | Metric | June 30, 2024 | December 31, 2023 | | :----------------------------------- | :------------ | :---------------- | | Cash, cash equivalents and short-term investments | $110.4 million | $145.3 million | | Working capital | $91.2 million | $110.5 million | Six-Month Cash Flow Summary | Cash Flow Activity | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(57.0) million | $(69.0) million | | Net cash provided by investing activities | $55.3 million | $72.9 million | | Net cash provided by financing activities | $21.7 million | $2.5 million | - Net proceeds from the April 2024 registered direct offering were $33.2 million87 - The company expects its cash runway to extend into the third quarter of 202588 Item 3. Quantitative and Qualitative Disclosures About Market Risk The company's primary market risk is interest rate sensitivity, which has resulted in a $3.5 million unrealized loss - Primary market risk is interest rate sensitivity, with an unrealized loss of $3.5 million in the investment portfolio as of June 30, 2024, due to increased interest rates89 - Exposure to foreign currency risk primarily from South Korean Won-denominated assets and transactions in Euros, British Pounds, and Canadian Dollars; no hedging activities are undertaken9091 - Inflation has not had a material effect on the business during the six months ended June 30, 202492 Item 4. Controls and Procedures Management concluded that disclosure controls and procedures were effective as of June 30, 2024 - Disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 202493 - No material changes in internal control over financial reporting occurred during the quarter ended June 30, 202494 Part II. Other Information Item 1. Legal Proceedings The company is involved in ongoing litigation with VGXI, Inc. and GeneOne Life Science, Inc - The company is prosecuting claims against VGXI for breach of supply agreement and defending against counterclaims96 - The company is prosecuting counterclaims against GeneOne for breach of the CELLECTRA Device License Agreement and defending against GeneOne's claims97 - A motion for summary judgment in the GeneOne litigation was denied on June 28, 202497 Item 1A. Risk Factors The company faces numerous risks including historical losses, capital requirements, and regulatory challenges - The company has incurred significant losses and expects to continue to do so, with an accumulated deficit of $1.7 billion as of June 30, 202499 - Success is highly dependent on obtaining FDA approval for novel DNA medicines and CELLECTRA delivery devices, which are complex drug-device combination products101103 - A manufacturing issue with the CELLECTRA 5PSP device has delayed the BLA submission for INO-3107 to mid-202575107 - The company will need substantial additional capital to fund research, development, and commercialization efforts102 Risks Related to Our Financial Position and Need for Additional Capital The company has a history of significant losses and will require substantial additional capital for future operations - Accumulated deficit of $1.7 billion as of June 30, 2024, with expectations of continued significant operating losses99 - Revenue generation is dependent on securing regulatory approvals and commercializing DNA medicine candidates and proprietary device technology101 - Substantial additional capital is needed for R&D, clinical testing, and market entry, with risks of dilution or operational curtailment if financing is not secured102103 Risks Related to Product Development, Manufacturing and Regulatory Approval FDA approval for drug-device combination products is uncertain, with potential delays from manufacturing issues - FDA approval for drug-device combination products is complex, lengthy, and uncertain, requiring substantial evidence of safety and efficacy103 - A manufacturing issue with the CELLECTRA 5PSP device has delayed the BLA submission for INO-3107 to mid-202575107 - Clinical trials are expensive, lengthy, and have uncertain outcomes; results from early stages or animal studies may not predict later success104 - The novelty of DNA medicines and CELLECTRA devices could lead to negative public perception, increased regulatory scrutiny, and challenges in market acceptance107 - Dependence on single-source suppliers for critical components and materials creates risks of supply disruptions, price increases, and delays108109 Risks Related to Reliance on Third Parties Product development depends on maintaining effective collaborations and managing third-party CROs - Loss or inadequate resource allocation by collaborators or partners could hinder product development and profitability113 - Agreements with government agencies are subject to termination and uncertain future funding, potentially impacting pipeline development113 - Reliance on CROs for clinical trials exposes the company to risks of delays, unreliable data, and increased costs if they fail to meet contractual duties or regulatory standards114 Risks Related to Commercialization of Our DNA Medicine Candidates Commercialization success is uncertain due to a lack of sales infrastructure and dependence on market acceptance and reimbursement - Lack of a substantial marketing and sales organization necessitates building internal capabilities or forming third-party agreements, which is expensive and time-consuming115 - Commercial success depends on broad market acceptance by the medical community and patients, influenced by safety, efficacy, ease of administration, and pricing116 - Uncertainty regarding coverage and reimbursement policies from third-party payors could limit product utilization and revenue generation117 - Healthcare reform measures, including cost containment programs and drug pricing regulations, could adversely affect product pricing and profitability117 Risks Related to Employee and Operational Matters The company faces operational risks from restructuring, litigation, competition, and dependence on key personnel - Corporate restructuring and headcount reductions (over 25% in 2022-2023) may cause increased attrition, reduced employee morale, and potential employment litigation117 - Ongoing litigation, including securities and contract disputes, is costly, time-consuming, and diverts management's attention118 - Success depends on retaining key management and scientific personnel and attracting new qualified talent in a competitive environment118 - Health epidemics (e.g., COVID-19) can disrupt clinical trials, manufacturing, and supply chains119 - Intense competition from large pharmaceutical and biotechnology companies with greater resources and expertise could impede commercialization120 - Risks from employee misconduct, non-compliance with regulations, and potential fraud could lead to regulatory sanctions and reputational harm128 - Uncertainties in Chinese laws, trade wars, and political unrest could adversely affect collaborations with Chinese companies and development efforts126 Risks Related to Our Intellectual Property Protecting intellectual property is difficult and costly, with risks from patent challenges and potential infringement litigation - Difficulty and cost in obtaining and maintaining patent, trademark, trade secret, and other IP protection, with uncertain legal principles and evolving laws130 - Risk that issued patents may not provide competitive advantages, could be challenged and invalidated, or may not cover design-arounds by competitors130 - Trade secrets are difficult to protect from unintentional or willful disclosure by employees, consultants, or collaborators131 - Potential for costly and time-consuming litigation if sued for infringing third-party intellectual property rights, which could lead to substantial damages or injunctions132 Risks Related to an Investment in Our Common Stock The common stock price is highly volatile, and anti-takeover provisions could limit market price - The price of common stock has been and may continue to be highly volatile, influenced by clinical trial results, market interest, and economic conditions133 - Management has broad discretion in using cash, cash equivalents, and investments, which may not always improve operating results or enhance stock value135 - Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control, potentially limiting the market price of common stock135 - The company has never paid and does not anticipate paying cash dividends, making capital appreciation the sole source of potential gain136 - Ability to utilize net operating loss carryforwards and other tax attributes may be limited by ownership changes or changes in tax laws137138 General Risk Factors Quarterly results are subject to fluctuations, and the company faces risks from economic conditions and data privacy regulations - Quarterly operating results may fluctuate significantly due to R&D expenses, clinical trial status, corporate transactions, and regulatory developments139 - Results of operations and liquidity needs are materially affected by market fluctuations, general economic conditions, and adverse developments in the financial services industry139 - Significant costs and demands on management arise from being a public company, including compliance with evolving laws and regulations141 - Stringent and evolving data privacy and security obligations (e.g., GDPR, CCPA) pose risks of regulatory actions, litigation, fines, and reputational harm144145 Item 5. Other Information The 2021 ATM Equity Offering Sales Agreement was terminated in August 2024 - No directors or officers adopted or terminated securities purchase/sale plans during Q2 2024146 - The 2021 ATM Equity Offering Sales Agreement was terminated in August 2024, after selling 4,289,403 shares for $93.6 million net proceeds146 Item 6. Exhibits This section lists the exhibits filed with the Form 10-Q, including XBRL documents and officer certifications - Includes XBRL Instance Document, Taxonomy Extension Schema, and Cover Page formatted as Inline XBRL147 - Lists corporate governance documents such as Certificate of Amendment to Certificate of Incorporation and Amended and Restated Bylaws149 - Contains certifications from the Chief Executive Officer and Chief Financial Officer as required by the Sarbanes-Oxley Act149 Signatures The report was duly signed by the CEO and CFO on August 8, 2024 - Report signed by Jacqueline E. Shea (President, CEO, and Director) and Peter Kies (CFO) on August 8, 2024150